Abstract:Hepatocellular carcinoma (HCC) is one of the most common types of cancer. Despite decades of research efforts, the search for novel biomarkers is still urgently needed for the diagnosis of HCC and the improvement of clinical outcomes. Previous studies of HCC clinical biomarkers have usually focused on serum and urine samples (e.g., serum Alpha-fetoprotein (AFP). However, cellular membrane proteins in lesion tissues are less used in HCC diagnosis. The abnormal expression of membrane glycoproteins in tumor lesions are considered as potential targets for tumor diagnosis and tumor therapies. Here, a lectin array has been employed to screen and identify abnormal glycopatterns and cellular membrane glycans in HCC lesion tissues compared with adjacent non-tumor tissues. We found that there was significantly less expression of Erythrina cristagalli (ECA) lectin binding (Galβ1-3/β1-4) glycans on the cellular membrane of HCC lesion tissues compared with those of adjacent non-tumor tissues. Immunohistochemistry analysis further showed that ECA-binding ability on the membrane proteins of HCC tissues progressively decreased in different tumor-node-metastasis (TNM) stages (stage I to stage III) as the malignancy of liver cancer increased. Receiver operating curve (ROC) analysis showed ECA-binding ability yielding a sensitivity of 85% and specificity of 75%, and a combination of ECA and AFP has better clinical diagnostic efficiency, yielding a sensitivity of 90% and specificity of 85%, than ECA or AFP assay alone. ECA pull-down followed by mass spectrometry further showed that there was significantly less expression of ECA binding membrane catalase (CAT) and prolyl 4-hydroxylase beta polypeptide (P4HB) in HCC tissues compared with the adjacent non-tumor tissues. The abnormally increased expression of total CAT and P4HB and decreased expression of galactosylated membrane CAT and P4HB in HCC cell lines were correlated with an HCC metastasis status. Our findings suggest that abnormal declined ECA-binding galatosylated membrane glycans and two galactosylated-CAT and P4HB glycoproteins in lesion tissues are potential biomarkers in the diagnosis and/or metastasis prediction for HCC.

Characteristics of Oligosaccharides of Glycoproteins in Bile from Patients with Bile Duct Carcinoma

Changes in terminal sialyl residues linked to N-glycans in the tissue of bile duct carcinoma and bile glycoproteins

Primary Studies on the Changes of Structures of Sugar Chains and the Mechanisms of N-acetylglucosaminyl-transferase(GnT) in Cholangiocarcinoma Bile

Alteration in N-Acetylglucosaminyltransferase Activities and Glycan Structure in Tissue and Bile Glycoproteins from Extrahepatic Bile Duct Carcinoma

Correlation of Glycosyltransferases Mrna Expression in Extrahepatic Bile Duct Carcinoma with Clinical Pathological Characteristics.

The Abnormal Glycopatterns of Salivary Glycoproteins in Esophageal Squamous Cell Carcinoma Patients

Comparative serum glycoproteomics of non-metastatic and metastatic hepatocellular carcinoma by lectin affinity technology

Structural Elucidation and in Vitro Antitumor Activity of a Novel Oligosaccharide from Bombyx Batryticatus.

Abnormal Galactosylated–Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer

Comparison of the composition of bile acids in bile of patients with adenocarcinoma of the pancreas and benign disease

Alteration of Liver N-glycome in Patients with Hepatocellular Carcinoma

Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis

Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma

Glycoproteomics investigation of human hepatocellular carcinoma cell lines

Detection of Bile Datura Stramonium Agglutinin Binding Activity in Combination with CEA for Diagnosis of Bile Duct Carcinoma

Bile Acids in Serum and Bile of Patients with Cholesterol Gallstone.

Benchmark N-glycoproteomics study of common differential tissue and serum N-glycoproteins of patients with hepatocellular carcinoma

Changes of glycoconjugates in human hepatocellular carcinoma

Comparative Proteomic Profiling Of Human Bile Reveals Ssp411 As A Novel Biomarker Of Cholangiocarcinoma

Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis

Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis.